Relationship of Patient Age and Tolerance to Carbonic Anhydrase Inhibitors

Shrader, C. Eric; Thomas, John V.; Simmons, Richard J.

doi:10.1016/s0002-9394(14)71915-4

Cited by 14 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6 Less favourable factors are angle recession, uveitic glaucoma, more than one operation, congenital glaucoma6,' and young individuals. 8 Pigment dispersion syndrome appears to give a good initial response, but often fails later and is thought to be due to trabecular sclerosis because of the greater absorption in the deeply pigmented trabecular meshwork so that the laser may cause further trabecular damage. 9 This study reviews the results of two years' experience of laser trabeculoplasty and studies factors which may influence the success or failure of the procedure.…”

mentioning

confidence: 99%

Two Years‘ Experience With Laser Trabeculoplasty

Higgins¹

1985

Australian and New Zealand Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Two Years‘ Experience With Laser Trabeculoplasty

Higgins¹

1985

Australian and New Zealand Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…However, the latter comparison shows a strong trend towards significance. Comparison of % changes in protein secretion rates on day 1 and day 11, show no statistically* significant differences (p > 0.05) in both treated and control eyes at both 10 and 60 minutes postdosing ( (11). In another example, the long-term treatment of glaucoma with timolol eyedrops has shown a tolerance to its intraocular pressure lowering property which was believed to be due to either changes in the number or affinity of the beta-adrenergic receptors (12).…”

Section: Analyses Of Datamentioning

confidence: 88%

“…For any medication given routinely for long-term treatment, there is a concern that tolerance for a drug may potentially develop (5)(6)(7)(8)(9)(10)(11)(12)(13)(14) requiring that additional drug be administered on subsequent dosing to maintain a therapeutic response. This leads to overexposure and if the drug stimulates more than one receptor, a disproportionality in response may develop.…”

Section: Introductionmentioning

confidence: 99%

Determination of Tolerance to Tear Protein Release Following a Twice a Day Topical Application of N,N-dimethyl-2-phenylethylamine HCl

Shirolkar¹,

Schoenwald²,

Barfknecht³

et al. 1995

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

In an effort to develop a long-term topically active tear stimulant, it was important to determine if tolerance developed following the repeated instillation of N,N-Dimethyl-2-phenylethylamine hydrochloride (AF2975) to the albino rabbit eye. New Zealand white rabbits were administered AF2975 (0.15%) twice a day (9 am and 4:30 pm) for 10 days. The right eye received the drug solution (50 microliters) and the left eye received an equal volume of the vehicle. Prior to dosing and at the end of first and last dose (10 and 60 minutes post-dosing), protein secretion was measured with the use of Schirmer tear test strips placed under the lower lid of each eye for five minutes. The strips absorbed tears from which protein was extracted. Eyes treated with AF2975 showed a statistically significant % increase in protein release compared to baseline values. Control eyes did not show statistically significant increases over baseline. A comparison of % changes from baseline in protein secretion rates after the first and last dose showed no significant differences in either treated or control eyes at 10 and 60 minutes postdosing. These results indicate that tolerance does not occur for protein secretion of topically administered AF2975 (0.15%) following a twice a day dosing schedule for 10 days to the rabbit eye.

show abstract

“…Acidosis may (171) or may not (172) play a part in the effect. Side effects, which can be quite severe, include anorexia, paresthesias, depression, acidosis, and low tolerance (173)(174).…”

Section: Carbonic Anhydrase Inhibitorsmentioning

confidence: 99%

A Synopsis of Recent Developments in Antiglaucoma Drugs

McLaughlin¹,

Chiou²

1985

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

Open-angle glaucoma is treated primarily with drugs, some of which have been used clinically for years. These drugs include: 1) cholinergic agonists that increase aqueous humor outflow, 2) adrenergic agonists and antagonist that affect both aqueous humor formation and outflow, and 3) carbonic anhydrase inhibitors that decrease aqueous humor formation.Several new classes of drugs are being tested for efficacy and mechanism of action. They include: 1) the D-isomer of timolol that reduces aqueous humor formation without producing adrenergic blockade, 2) dopaminergic agonists and antagonists, including bromocriptine and butyrophenones that reduce intraocular pressure, and 3) cannabinoids that reduce aqueous humor formation and increase outflow.In addition, several other types of drugs, such as prostaglandins, diuretics, Na+,K+-ATPase inhibitors, and adenyl cyclase stimulators are just now beginning to be studied.

show abstract

Relationship of Patient Age and Tolerance to Carbonic Anhydrase Inhibitors

Cited by 14 publications

References 9 publications

Two Years‘ Experience With Laser Trabeculoplasty

Two Years‘ Experience With Laser Trabeculoplasty

Determination of Tolerance to Tear Protein Release Following a Twice a Day Topical Application of N,N-dimethyl-2-phenylethylamine HCl

A Synopsis of Recent Developments in Antiglaucoma Drugs

Contact Info

Product

Resources

About